Academic-Industrial Partnership to Develop Clinical Brain Cancer Imaging

学术与工业合作开发临床脑癌成像

基本信息

批准号：
8437368
负责人：
Peter CM Van Zijl
金额：
$ 49.14万
依托单位：
JOHNS HOPKINS UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-02-05 至 2018-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8437368
关键词：
Academia Address Affect Aftercare Amides Amplifiers Animal Model Appearance Baltimore Biological Biological Markers Biopsy Brain Neoplasms Brain imaging Characteristics Chemicals Clinic Clinical Clinical Data Clinical Sciences Contracts Data Detection Diagnosis Diffusion Emerging Technologies Exhibits Gadolinium Glioblastoma Glioma Goals Gold Healthcare Hospitals Human Image Imaging Techniques Imaging technology Incidence Industry Institutes International Laboratory Research Magnetic Resonance Imaging Magnetic Resonance Spectroscopy Malignant Glioma Malignant neoplasm of brain Methodology Modality Molecular Morphologic artifacts New York Newly Diagnosed Noise Ohio Operative Surgical Procedures Pathology Patient Care Patients Perfusion Physiologic pulse Proteins Proteomics Protocols documentation Protons Radiation Radiation necrosis Radiation therapy Recurrence Recurrent tumor Reporting Reproducibility of Results Research Research Personnel Scheme Signal Transduction Signaling Protein Site System Techniques Technology Technology Transfer Testing Texas Time Tissues Translating Translations Tumor Tissue Universities Vendor Work absorption abstracting base cancer imaging chemotherapy computerized data processing data acquisition design gadolinium oxide in vivo innovation meetings molecular imaging new technology novel pre-clinical preclinical study public health relevance radiofrequency response standard of care temozolomide transmission process treatment effect treatment response trend tumor

项目摘要

DESCRIPTION (provided by applicant): The overall goal of this academic-industrial partnership between researchers at Johns Hopkins University and Philips Healthcare/Philips Research is to develop and optimize the novel amide proton transfer (APT) imaging technique for efficient and reliable detection of malignant brain tumors and assessment of treatment response. APT imaging can provide endogenous contrast related to mobile protein content in tissue. Preclinical studies and clinical data suggest that APT imaging may provide unique information about the presence and grade of brain tumors, as revealed by MRI-guided proteomics and in vivo MR spectroscopy. Notably, we recently demonstrated in animal models that the APT-MRI signal is a unique imaging biomarker to distinguish between radiation necrosis and active tumor tissue. Similar to other MRI techniques, the ultimate goal for APT imaging is the standardized use in a clinical setting. However, current APT imaging protocols are far from being optimized. A main reason is that the APT experimental parameters are often limited by scanner hardware constraints, particularly with respect to amplifier duty-cycle and specific absorption rate requirements. In addition to pulse sequence parameter differences, leading to inconsistent effect sizes, data processing strategies vary and may affect the reproducibility of results between hospitals. Therefore, there is an urgent need for industry and academia to work together to develop this emerging technology into a clinically viable, easy-to-use, and reproducible approach. To accomplish this, we (researchers at JHU and Philips) agreed to establish a cooperation to achieve an accelerated APT translation. Together, we formulated the following two specific aims: (1) Optimize and standardize APT imaging technology on 3T human MRI systems; and (2) Test the methodologies developed in Aim 1 on patients with brain tumors. APT imaging has the potential to introduce an entirely new molecular MRI methodology into the clinic that can detect endogenous cellular protein signals in biological tissue non-invasively. Thi research will provide the standard optimized approaches required to translate this new technology into the clinic.

描述（由申请人提供）：约翰·霍普金斯大学和飞利浦医疗保健/飞利浦研究中心的研究人员之间的学术-工业合作伙伴关系的总体目标是开发和优化新型酰胺质子转移 (APT) 成像技术，以有效、可靠地检测恶性肿瘤脑肿瘤和治疗反应评估。 APT 成像可以提供与组织中可移动蛋白含量相关的内源对比度。临床前研究和临床数据表明，正如 MRI 引导的蛋白质组学和体内 MR 光谱所揭示的那样，APT 成像可以提供有关脑肿瘤的存在和分级的独特信息。值得注意的是，我们最近在动物模型中证明，APT-MRI 信号是区分放射性坏死和活动性肿瘤组织的独特成像生物标志物。与其他 MRI 技术类似，APT 成像的最终目标是在临床环境中标准化使用。然而，当前的 APT 成像协议还远未得到优化。主要原因是 APT 实验参数通常受到扫描仪硬件限制的限制，特别是放大器占空比和特定吸收率要求方面。除了脉冲序列参数差异导致效应大小不一致之外，数据处理策略也存在差异，可能会影响医院之间结果的可重复性。因此，迫切需要工业界和学术界共同努力，将这一新兴技术发展成为临床上可行、易于使用和可重复的方法。为了实现这一目标，我们（约翰霍普金斯大学和飞利浦的研究人员）同意建立合作，以实现加速 APT 翻译。我们共同制定了以下两个具体目标：（1）优化和标准化3T人体MRI系统上的APT成像技术； (2) 在脑肿瘤患者身上测试目标 1 中开发的方法。 APT 成像有可能将一种全新的分子 MRI 方法引入临床，可以非侵入性地检测生物组织中的内源细胞蛋白信号。这项研究将提供将这项新技术转化为临床所需的标准优化方法。